A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC

Abstract More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most patients inevitably develop crizotinib resistance due...

Cijeli opis

Bibliografski detalji

Glavni autori:	Yue Lu, Zhenzhen Fan, Su‐Jie Zhu, Xiaoxing Huang, Zhongji Zhuang, Yunzhan Li, Zhou Deng, Lei Gao, Xuehui Hong, Ting Zhang, Li Li, Xihuan Sun, Wei Huang, Jingfang Zhang, Yan Liu, Baoding Zhang, Jie Jiang, Fu Gui, Zheng Wang, Qiyuan Li, Siyang Song, Xin Huang, Qiao Wu, Lanfen Chen, Dawang Zhou, Jianming Zhang, Cai‐Hong Yun, Liang Chen, Xianming Deng
Format:	Artigo
Jezik:	Inglês
Izdano:	Springer Nature 2021-11-01
Serija:	EMBO Molecular Medicine
Teme:	acquired resistance mutations ALK inhibitor crizotinib EML4‐ALK nonsmall cell lung cancer
Online pristup:	https://doi.org/10.15252/emmm.202114296
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!